|
 For more information please contact:
Alison Zeigle
212.554.5469
alison@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar » |
|
Encorium Group, Inc. (NASDAQ: ENCO)
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.
|
|
January 14, 2010:
Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board;
- download word.doc (40 Kb) »
|
November 16, 2009:
Encorium Reports Third Quarter 2009 Financial Results; Announces Date of Annual Stockholder Meeting
- download word.doc (40 Kb) »
|
October 19, 2009:
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
- download word.doc (40 Kb) »
|
September 9, 2009:
Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win
- download word.doc (40 Kb) »
|
August 31, 2009:
Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity
- download word.doc (40 Kb) »
|
August 27, 2009:
Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
- download word.doc (40 Kb) »
|
August 24, 2009:
Encorium Reports Second Quarter 2009 Financial Results
- download word.doc (40 Kb) »
|
July 17, 2009:
Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
- download word.doc (40 Kb) »
|
July 1, 2009:
Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
- download word.doc (40 Kb) »
|
June 18, 2009:
Encorium Group Amends LOI with Respect to the Sale of its U.S. Business;
- download word.doc (40 Kb) »
|
May 19, 2009:
Encorium Reports First Quarter 2009 Financial Results
- download word.doc (40 Kb) »
|
May 18, 2009:
Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
- download word.doc (40 Kb) »
|
May 11, 2009:
Encorium Group Enters into Non-Binding Letters of Intent
- download word.doc (40 Kb) »
|
April 29, 2009:
Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
- download word.doc (40 Kb) »
|
April 27, 2009:
Encorium Reports Fourth Quarter and Full Year 2008 Financial Results
- download word.doc (40 Kb) »
|
April 27, 2009:
Encorium Group Signs Approximately $2.0 Million of New Business Contracts
- download word.doc (40 Kb) »
|
April 24, 2009:
Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing
- download word.doc (40 Kb) »
|
March 31, 2009:
Encorium Group Postpones Filing of 10-K as it Evaluates Goodwill Impairment Charge
- download word.doc (40 Kb) »
|
January 27, 2009:
Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
- download word.doc (40 Kb) »
|
November 28, 2008:
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
- download word.doc (40 Kb) »
|
November 26, 2008:
Encorium Reports Third Quarter 2008 Financial Results
- download word.doc (40 Kb) »
|
November 18, 2008:
Encorium Group Signs $6.5 Million of New Business Contracts Mainly Consisting of Oncology Clinical Trials with a U.S. Biopharmaceutical Company
- download word.doc (40 Kb) »
|
November 11, 2008:
Encorium Appoints Shahab Fatheazam to its Board of Directors
- download word.doc (40 Kb) »
|
October 6, 2008:
Encorium Announces Stock Buyback; Provides Business and Financial Update
- download word.doc (40 Kb) »
|
October 1, 2008:
Encorium Announces Receipt of Nasdaq Letter Regarding Compliance with Nasdaq's Independent Director and Audit Committee Requirements
- download word.doc (40 Kb) »
|
September 22, 2008:
Encorium Announces the Initiation of a Strategic Partnership with Prologue Research after the Postponement of Negotiations Regarding its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investigated
- download word.doc (40 Kb) »
|
September 22, 2008:
Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials.
- download word.doc (40 Kb) »
|
September 10, 2008:
Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
- download word.doc (40 Kb) »
|
